IDEAS home Printed from https://ideas.repec.org/a/epw/clinic/v3y2022i3id12202.html

Is Artesunate the Best Partner of Gemcitabine in Pancreatic Cancer?

Author

Listed:
  • Tomas Koltai

Abstract

Pancreatic adenocarcinoma (PDAC) is still one of the most malignant and difficult to treat cancers. The therapeutic protocols in use, such as gemcitabine, gemcitabine associated with nab-paclitaxel and/or cisplatin or the FOLFIRINOX scheme have added very little to PDAC outcome. It is clear by now, that none of them can do the job alone. The more than 3,300 trials registered in clinicaltrials.gov is the best proof that research has not yet found an adequate response to tackle this disease. Thus, an innovative search is badly needed. As part of this investigation we came across a phytotherapeutic product that has been very successful for the treatment of falciparum- and vivax- caused malaria: artemisinin derivatives. These derivatives showed very low toxicity for humans and have been tested in millions of patients with paludism. Interestingly, they have also shown important anti-cancer properties. Regarding PDAC in particular there is strong evidence supporting not only an additive effect to gemcitabine without a concomitant increase in human toxicity, but also decreased resistance. This mini-review will discuss the evidence showing that artemisinin derivatives can be the best possible association with gemcitabine for PDAC chemotherapeutic treatment.

Suggested Citation

  • Tomas Koltai, 2022. "Is Artesunate the Best Partner of Gemcitabine in Pancreatic Cancer?," European Journal of Clinical Medicine, European Open Science, vol. 3(3), pages 1-12, May.
    • Handle: RePEc:epw:clinic:v:3:y:2022:i:3:id:12202
    DOI: 10.24018/clinicmed.2022.3.3.202
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/clinicmed/article/view/12202
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/clinicmed/article/download/12202/2469
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/clinicmed.2022.3.3.202?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Guo Chen & Yin Luo & Kurt Warncke & Youwei Sun & David S. Yu & Haian Fu & Madhusmita Behera & Suresh S. Ramalingam & Paul W. Doetsch & Duc M. Duong & Michael Lammers & Walter J. Curran & Xingming Deng, 2019. "Acetylation regulates ribonucleotide reductase activity and cancer cell growth," Nature Communications, Nature, vol. 10(1), pages 1-16, December.
    2. U. Eckstein-Ludwig & R. J. Webb & I. D. A. van Goethem & J. M. East & A. G. Lee & M. Kimura & P. M. O'Neill & P. G. Bray & S. A. Ward & S. Krishna, 2003. "Artemisinins target the SERCA of Plasmodium falciparum," Nature, Nature, vol. 424(6951), pages 957-961, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Keywords

      ;
      ;
      ;
      ;
      ;
      ;

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:clinic:v:3:y:2022:i:3:id:12202. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/clinicmed .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.